Clinical efficacy and safety of amiodarone on patients with acute myocardial infarction combined with atrial fibrillation
10.13699/j.cnki.1001-6821.2015.12.003
- VernacularTitle:胺碘酮治疗急性心肌梗死合并心房颤动的临床疗效及安全性评价
- Author:
Bin LAI
1
;
Zhi-Hua DENG
Author Information
1. 张家口市张北县医院 内科
- Keywords:
acute myocardial infarction;
atrial fibrillation;
amiodarone;
clinical effect;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(12):1085-1087
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of amiodarone in the treatment of acute myocardial infarction combined with atrial fibrillation.Methods A total of 51 patients with acute myocardial infarction and atrial fibrillation were recruited from January 2012 to October 2014 in our hospital.And they were randomly divided into treat-ment group ( n=26 ) and control group ( n=25 ) .Patients in the treat-ment group were treated with amiodarone 100 mg +0.9%NaCl solution 20 mL by intravenous injection within 6 min and followed by amiodarone 0.5 -1.0 mg? min-1 by intravenous drip until back to sinus rhythm. Patients in the control group were treated with cedilanid 0.4 mg +5%glucose 20 mL by intravenous injection within 5 min.The data of atrial fibrillation control rate in the first 24 hours, the sinus rhythm sustain rate in the first month and adverse drug reactions were compared between the two groups.Results The artial fibrillation control rate was 53.8%and 24.0% in the treatment and control group respectively , indicating treatment group was significantly higher than control group ( P<0.05 ) . The sinus rhythm sustain rate in treatment group was significant higher than that in control group ( 88.5% vs 48.0%, P <0.05 ) .And the incidence of adverse drug reactions in the treatment group were much lower than that in the control group (7.6%vs 40.0%, P<0.05).Conclusion Amiodarone is superior to cedilanid in the treatment of patients with acute myocardial infarction combined with atrial fibrillation for the aspect of clinical efficacy and safety.
